Published 8 days ago • loading... • Updated 8 days ago

Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases

Open the article to view the coverage from Intelligence360 News

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

Expansión

Inveready Achieves a Return of More than Four Times with Its Second Biotech Background

Inveready, Spanish venture capital manager, has obtained a return on invested capital (MOIC) of 4.3 times in the liquidation of its Inveready Innvierte Biotech II fund,...

8 days ago

Read Full Article

Intelligence360 News

Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases

Open the article to view the coverage from Intelligence360 News

8 days ago

Read Full Article

pharmafile.com

Pila Pharma raises SEK 20m to advance new oral obesity treatment - Pharmafile

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development of its oral obesity treatment, XEN-D0501. The funding round includes stock options for additional financing over the next nine months. Founded by former Novo Nordisk researcher Dorte X Gram, who played a leading role in […] The post Pila Pharma raises SEK 20m to advance new oral obesity treatment appeared first on Pharmaf…

8 days ago

Read Full Article

European Pharmaceutical Manufacturer

Biotech founded by ex-Novo reseacher raises capital for oral obesity treatment

The biotech company, Pila Pharma, is raising 20 million Swedish kronor in an almost fully covered capital raise, which includes a stock option for future use.

8 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year